Integrated Pharmacokinetic/Pharmacodynamic Analysis for Determining the Minimal Anticipated Biological Effect Level of a Novel Anti-CD28 Receptor Antagonist BMS-931699

• Published in: The Journal of pharmacology and experimental therapeutics 2015-12, Vol.355 (3), p.506-515
• Main Authors: Yang, Zheng, Wang, Haiqing, Salcedo, Theodora W, Suchard, Suzanne J, Xie, Jenny H, Schneeweis, Lumelle A, Fleener, Catherine A, Calore, James D, Shi, Rong, Zhang, Sean X Y, Rodrigues, A David, Car, Bruce D, Marathe, Punit H, Nadler, Steven G
• Format: Article
• Language: English
• Subjects: Algorithms; Animals; Antibodies - pharmacology; Body Surface Area; CD28 Antigens - antagonists & inhibitors; Dose-Response Relationship, Drug; Female; Hemocyanins - antagonists & inhibitors; Humans; Lymphocyte Culture Test, Mixed; Macaca fascicularis; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Microbial Sensitivity Tests; Monocytes - drug effects; Polyethylene Glycols - pharmacokinetics; Polyethylene Glycols - pharmacology
• ISSN: 0022-3565; 1521-0103
• DOI: 10.1124/jpet.115.227249

BMS-931699 (lulizumab pegol), a domain antibody (dAb) conjugated with 40-kDa branched polyethylene glycol, is a human anti-CD28 receptor antagonist under development for the treatment of inflammatory and autoimmune diseases. In the present work, the minimal anticipated biologic effect level (MABEL) was determined for BMS-931699 by integrating all the available preclinical data. The relevance of the in vitro mixed lymphocyte reaction (MLR) assay to a whole blood CD28 receptor occupancy (RO) assessment, as well as the relationship between the CD28 RO and the inhibition of T-cell-dependent antibody response to keyhole limpet hemocyanin in vivo, was demonstrated through an integrated pharmacokinetic/pharmacodynamic analysis using anti-hCD28 dAb-001 (differing from BMS-931699 by two additional amino acids at the N-terminus) and a mouse surrogate. Based on this analysis, the EC10 value (0.32 nM) from the human MLR assay and the human plasma volume (0.04 l/kg) were employed to calculate the MABEL (0.01 mg) of BMS-931699 in humans, with a CD28 RO predicted to be ≤10%. The estimated MABEL dose was threefold higher than the value derived from the binding constant and twofold less than the MABEL converted from animal efficacy studies based on the body surface area. Furthermore, it was 2900-fold lower than the human equivalent dose derived from the no observed adverse effect level in monkeys (15 mg/kg/week for 5 doses, intravenous dosing) with a 10-fold safety factor applied. Therefore, the MABEL dose represented a sound approach to mitigate any potential risk in targeting CD28 and was successfully used as the first-in-human starting dose for BMS-931699.